Class 10 · Metabolic · GLP-1 receptor agonists · incretin therapy · FDA-approved · daily vs weekly · boxed warning
Liraglutide vs DulaglutideVictoza / Saxenda & Trulicity · two GLP-1 strategies, one receptor
Liraglutide and dulaglutide are GLP-1 receptor agonists — prescription injectables that copy the gut hormone GLP-1 to help control blood sugar, slow the stomach, increase fullness, and trigger insulin only when glucose is high. Liraglutide is daily (Victoza for diabetes, Saxenda for weight management); dulaglutide is once-weekly (Trulicity for diabetes and cardiovascular-risk reduction). They are medicines, not wellness peptides, and both carry a thyroid-tumor boxed warning.
Both activate the GLP-1 receptor to drive glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The clinical contrast is exposure and indication: liraglutide is a once-daily acylated analog (~13 h half-life) with separate diabetes (Victoza) and obesity (Saxenda, 3.0 mg) labels; dulaglutide is a once-weekly IgG4-Fc fusion (~5-day half-life) for T2D and cardiovascular-risk reduction. Cardiovascular benefit is anchored by LEADER (liraglutide) and REWIND (dulaglutide).
The pair illustrates two solutions to native GLP-1's ~1.5–2-minute half-life. Liraglutide (C₁₇₂H₂₆₅N₄₃O₅₁, 3751.2 Da) is 97% homologous to GLP-1(7-37) with an Arg³⁴ substitution and a C16 palmitoyl/γ-Glu acyl chain that binds albumin and resists DPP-4; dulaglutide (~63 kDa) fuses two modified GLP-1 analogs (Gly⁸, Glu²², Gly³⁶) to a modified human IgG4 Fc via peptide linkers, using size to slow renal clearance. Both signal through GLP-1R–Gs–cAMP; both reduced MACE in dedicated cardiovascular outcome trials.
BOXED WARNING · thyroid C-cell tumors
Both liraglutide and dulaglutide carry a boxed warning for thyroid C-cell tumors observed in rodents; they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2). The human relevance of the rodent findings is not determined. This page is educational only — it does not provide personalized dosing, eligibility determination, or treatment recommendations. Provider screening and monitoring are required.
01 · At a glance
Two GLP-1 agonists, side by side.
Liraglutide and dulaglutide share a receptor and a mechanism but differ in dosing frequency, molecular engineering, and labeled scope. Both are high-evidence, FDA-approved prescription drugs with cardiovascular outcome data — not research peptides — and both demand contraindication screening, side-effect monitoring, and interaction review. The defining practical split: liraglutide is daily with a dedicated obesity pathway; dulaglutide is weekly and diabetes/CV-focused.
🔑
Shared mechanism
GLP-1R agonist
Both activate the GLP-1 receptor for glucose-dependent insulin secretion and glucagon suppression. Grade A.
📅
Dosing frequency
Daily vs weekly
Liraglutide once daily (~13 h); dulaglutide once weekly (~5 d) — the main adherence difference.
⚖️
Obesity pathway
Liraglutide only
Liraglutide has a dedicated weight-management label (Saxenda); dulaglutide does not. Grade A.
❤️
CV outcomes
LEADER / REWIND
LEADER: MACE HR 0.87; REWIND: HR 0.88 in a broad population. Grade A.
⛔
Boxed warning
Thyroid C-cell
Both contraindicated with personal/family MTC or MEN 2 history. Grade A.
🤢
Main side effects
GI (nausea)
Nausea, vomiting, diarrhea, constipation — class GI effects, dose/titration-related. Grade A.
🧬
Engineering
Acyl vs Fc-fusion
Liraglutide: fatty-acid acylation vs dulaglutide: IgG4-Fc fusion — two half-life strategies.
🚫
Not
"Same as semaglutide"
Neither should be marketed as equivalent to semaglutide/tirzepatide for weight loss, nor stacked together. Grade D (blocked).
02 · Mechanism of action
One receptor, two engineering paths.
Both drugs do the same thing pharmacologically: they are long-acting mimics of GLP-1, an incretin hormone the gut releases after eating. The clever part is not the receptor biology — which they share — but how each molecule was engineered to survive in the body long enough to dose daily (liraglutide) or weekly (dulaglutide) instead of every two minutes like native GLP-1.
Grade A
🔑
1 · GLP-1 receptor activation
Both bind and switch on the GLP-1 receptor, the same target as the body's own incretin hormone.
Clinical significance: Activation drives glucose-dependent insulin secretion and reduces glucagon when glucose is elevated — so glucose-lowering is largely self-limiting, keeping monotherapy hypoglycemia risk low.
Molecular detail: The GLP-1 receptor is a class-B GPCR coupled to Gs → adenylyl cyclase → cAMP in pancreatic beta cells; rising cAMP potentiates glucose-stimulated insulin release. Both agents bind and activate this receptor like endogenous GLP-1(7-37).
Grade A
🍽️
2 · Gastric emptying & appetite
They slow the stomach and signal fullness, blunting post-meal glucose and reducing intake.
Clinical significance: Slowed gastric emptying lowers postprandial glucose, and central appetite effects reduce caloric intake — the basis for weight loss and the rationale for liraglutide's obesity label.
Molecular detail: Appetite effects are mediated via hypothalamic and hindbrain GLP-1 receptors. Delayed gastric emptying is also clinically relevant around procedures/anesthesia and for the absorption timing of some oral drugs.
Grade A
🧬
3 · Glucagon suppression
They quiet inappropriate glucagon, reducing the liver's glucose output after meals.
Clinical significance: Glucose-dependent glucagon suppression reduces hepatic glucose output without abolishing the protective glucagon response to true hypoglycemia.
Molecular detail: The glucose-dependence of both insulinotropic and glucagonostatic effects is the defining safety feature of the incretin class — distinguishing GLP-1 RAs from sulfonylureas and insulin.
Grade A
⏱️
4 · Liraglutide — acylation strategy
A fatty-acid tail lets liraglutide cling to albumin and dodge the enzyme that destroys native GLP-1.
Clinical significance: A C16 palmitoyl chain on Lys²⁶ (via a γ-Glu spacer) plus an Arg³⁴ substitution gives ~97% GLP-1 homology, albumin binding, DPP-4 resistance, and a ~13-hour half-life suitable for once-daily dosing.
Molecular detail: Self-association at the injection site plus reversible albumin binding delays absorption and clearance. The same acylation principle (with a longer linker/diacid) underlies semaglutide's weekly profile.
Grade A
🧱
5 · Dulaglutide — Fc-fusion strategy
Dulaglutide bolts the GLP-1 peptide onto an antibody fragment, so it's simply too big to clear quickly.
Clinical significance: Two modified GLP-1 analogs fused to a modified human IgG4 Fc make a ~63 kDa homodimer that resists DPP-4 and renal clearance, giving a ~5-day half-life for weekly dosing.
Molecular detail: GLP-1 substitutions (Gly⁸ for DPP-4 resistance, Glu²², Gly³⁶) preserve receptor binding; the IgG4 Fc is engineered to minimize Fcγ-receptor binding and half-antibody formation, so the antibody scaffold provides longevity, not immune function.
Grade A
❤️
6 · Cardiometabolic & renal effects
Beyond glucose, both lower cardiovascular risk and show kidney-protective signals.
Clinical significance: Liraglutide reduced MACE and mortality in LEADER and dulaglutide reduced MACE in the broad REWIND population, with renal composite benefits driven largely by reduced albuminuria.
Molecular detail: Proposed mediators include weight, blood pressure, lipid, glycemic, and albuminuria effects plus direct vascular actions; mediation analyses attribute much of liraglutide's MACE benefit to HbA1c and UACR changes. Guidelines now prioritize GLP-1 RAs with proven CV benefit in T2D with CV/kidney risk.
L3 · Cascade
Shared incretin cascade — from receptor to outcomes
💉 GLP-1 RA
daily / weekly SC
→
🔑 GLP-1R
Gs · cAMP
→
⚙️ Incretin effects
insulin · glucagon · gut · appetite
→
📉 Glycemia & weight
A1c · PPG · weight
→
❤️ ↓ MACE
LEADER · REWIND
L2 · Engineering contrast
Two half-life strategies, compared
Property
Liraglutide
Dulaglutide
Strategy
Fatty-acid acylation
IgG4-Fc fusion
Size
3751 Da peptide
≈ 63 kDa biologic
GLP-1 homology
97%
90%
DPP-4 resistance via
Acylation + albumin binding
Gly⁸ substitution + size
Half-life
≈ 13 h
≈ 5 days
Frequency
Daily
Weekly
L2 · Shared effects, graded
Mechanism strength map (class)
Effect
Strength
Basis
Glucose-dependent insulin secretion
High
Label
Glucagon suppression
High
Label
Slowed gastric emptying
High
Label / review
Appetite / weight reduction
High (lira) / Moderate (dula)
SCALE / class
MACE reduction
High
LEADER / REWIND
Renal (albuminuria) benefit
Moderate
Outcome analyses
03 · Dosing protocol & models
Three labels, three titrations.
Liraglutide and dulaglutide span three distinct FDA labels — Victoza (liraglutide, diabetes), Saxenda (liraglutide, weight management), and Trulicity (dulaglutide, diabetes + CV risk). Each has its own starting dose, titration cadence, and maximum. The panels below separate them, contrast the titrations, and lay out the contraindication screening every GLP-1 start requires. All figures are label education, not a prescription — GLP-1 therapy requires clinician review, contraindication screening, and monitoring.
Approved-label education · provider-managed
Victoza is approved for T2D glycemic control (adults and children ≥10) and to reduce MACE in adults with T2D and established cardiovascular disease; Saxenda is approved for chronic weight management in qualifying adults and adolescents ≥12; Trulicity is approved for T2D glycemic control (≥10) and to reduce MACE in adults with T2D and established CVD or multiple CV risk factors. The calculator here is a label-reference tool only — no personalized dosing, eligibility, or insulin-adjustment output.
Titration principle
Every GLP-1 RA is started low and stepped up to limit GI side effects. Liraglutide begins at 0.6 mg daily; dulaglutide begins at 0.75 mg weekly. Hypoglycemia risk rises when combined with insulin or sulfonylureas, which may need dose reduction under clinician guidance.
Victoza — liraglutide for type 2 diabetes
Daily · 0.6 → 1.2 → 1.8 mg
Grade A
Indication
T2D glycemic control (adults & ≥10 y) and MACE reduction in adults with T2D + established CVD.
Start
0.6 mg SC once daily for 1 week (initiation dose to reduce GI effects; not effective for glycemic control).
Titrate
Increase to 1.2 mg; if needed, to 1.8 mg daily (label maximum for Victoza).
Pen
6 mg/mL multi-dose pen (18 mg / 3 mL); any time of day, with or without food.
CV evidence
LEADER demonstrated MACE reduction at the 1.8 mg dose.
Screen for MTC/MEN 2 (boxed warning). Reduce insulin/sulfonylurea as needed to limit hypoglycemia. Not for type 1 diabetes or DKA.
Victoza · titration
Liraglutide T2D schedule
Step
Dose
Note
Week 1
0.6 mg daily
Initiation (GI tolerance)
Then
1.2 mg daily
Therapeutic
If needed
1.8 mg daily
Maximum (LEADER dose)
Saxenda — liraglutide for weight management
Daily · 0.6 → 3.0 mg (higher-dose pathway)
Grade A
Indication
Chronic weight management with reduced-calorie diet + activity in adults with obesity/overweight + a comorbidity, and qualifying adolescents ≥12.
Titration
0.6 mg weekly up-titration → 1.2 → 1.8 → 2.4 → 3.0 mg daily; escalate to limit GI effects.
Maintenance
3.0 mg once daily (Saxenda label maximum) — higher than the 1.8 mg Victoza max.
Stopping rule
Per label, reassess/discontinue if a meaningful weight-loss threshold is not reached after a defined interval at the maintenance dose.
Evidence
SCALE (liraglutide 3.0 mg, 56 wk) produced significantly greater weight loss than placebo.
Same molecule as Victoza but a distinct product, indication, and dose ceiling — do not conflate the two labels. Same MTC/MEN 2 contraindication applies.
Saxenda · titration
Liraglutide weight-management schedule
Week
Daily dose
Note
1
0.6 mg
Initiation
2 / 3 / 4
1.2 / 1.8 / 2.4 mg
Weekly steps
5+
3.0 mg
Maintenance (max)
Trulicity — dulaglutide for type 2 diabetes
Weekly · 0.75 → 1.5 → 3.0 → 4.5 mg
Grade A
Indication
T2D glycemic control (adults & ≥10 y) and MACE reduction in adults with T2D + established CVD or multiple CV risk factors.
Start
0.75 mg SC once weekly (an effective dose; no mandatory initiation step).
Titrate
May increase to 1.5 mg, then 3.0 mg, then 4.5 mg weekly for additional glycemic control (max 4.5 mg).
Pen
Single-dose auto-injector (0.5 mL); fixed dose per pen; any day, any time, ± food.
CV evidence
REWIND demonstrated MACE reduction across a broad population including primary prevention.
Weekly product — do not convert casually from a daily GLP-1. Screen for MTC/MEN 2. Reduce insulin/sulfonylurea as needed.
Trulicity · titration
Dulaglutide weekly schedule
Step
Weekly dose
Note
Start
0.75 mg
Effective starting dose
Step
1.5 mg
Common maintenance
Step
3.0 mg
Added control (AWARD-11)
Max
4.5 mg
Label maximum
Titration & conversion logic
Daily vs weekly — not interchangeable
Grade A
No casual conversion
There is no simple mg-for-mg switch between a daily and a weekly GLP-1; conversions are clinician-directed.
Head-to-head
In AWARD-6, weekly dulaglutide 1.5 mg matched daily liraglutide 1.8 mg on A1c but produced less weight loss.
GI-gated up-titration
Advance only as GI tolerability allows; slowing titration mitigates nausea for both agents.
No duplicate incretin
Never use two GLP-1 (or GLP-1/GIP) agents together — duplicate incretin therapy adds risk without clear benefit.
This atlas does not generate switch doses, eligibility, or insulin adjustments. The schedules shown are published label steps for education only.
Side-by-side
Label dose ranges
Product
Range
Frequency
Victoza (lira, T2D)
0.6 → 1.8 mg
Daily
Saxenda (lira, obesity)
0.6 → 3.0 mg
Daily
Trulicity (dula, T2D)
0.75 → 4.5 mg
Weekly
Pre-start screening & safety gates
What must be checked before any GLP-1
Grade A
Thyroid history
Block if personal/family history of MTC or MEN 2 (boxed-warning contraindication).
Pancreatitis
History of pancreatitis warrants caution/specialist review.
Hypoglycemia risk
Review insulin/sulfonylurea use; reduce as needed.
GI / gastroparesis
Severe GI disease or gastroparesis warrants caution and provider review.
Pregnancy
Require reproductive review; weight-loss GLP-1 use generally inappropriate in pregnancy.
Procedures
Flag upcoming surgery/anesthesia — delayed gastric emptying may matter periprocedurally.
Blocked outputs: autonomous patient-specific protocols, eligibility determination, research-chemical/compounded substitution, and "same as semaglutide/tirzepatide" claims.
Hard gates
Screening decision table
Finding
Action
Gate
MTC / MEN 2 history
Do not use
Contraindication
Serious prior hypersensitivity
Do not use
Contraindication
Insulin / sulfonylurea
Reduce / monitor
Hypoglycemia
Upcoming procedure
Anesthesia review
Aspiration risk
L2 · Approved-label reference only
Label-Reference Dose Calculator
Reference only — shows the published label dose, frequency, and pen reference for each product. It does not prescribe therapy, select a medication, replace FDA pen instructions, determine eligibility, or convert between agents. GLP-1 receptor agonists require clinician review, contraindication screening, and monitoring. Mixing math is not a prescription or use recommendation.
Label dose
—
Frequency
—
Pen reference
—
Label maximum
—
Basis
—
04 · Interactions & combination logic
Care-team regimens, not "stacks".
In real diabetes and cardiometabolic care, GLP-1 agonists are combined with other agents under a clinician's direction — these are managed regimens, not bodybuilding-style stacks. The cardinal rule is simple: never duplicate incretin therapy. Liraglutide and dulaglutide must never be used together, nor with any other GLP-1 or GLP-1/GIP agent.
+ Metformin
Common, complementary
GLP-1 RAMetformin
The most common T2D pairing — complementary mechanisms with low intrinsic hypoglycemia risk. Monitor GI tolerability since both can cause GI effects. Grade A.
Element
Note
Gate
Metformin
First-line T2D base
Monitor GI
+ SGLT2 Inhibitor
Cardiorenal pairing
GLP-1 RASGLT2i
Increasingly common in cardiometabolic/CKD risk management, combining complementary CV/renal benefits. Monitor hydration, renal function, and ketoacidosis-risk context. Grade A/B.
Element
Concern
Gate
SGLT2 inhibitor
Hydration / DKA context
Monitor renal/fluid
+ Basal Insulin
Selected patients
GLP-1 RABasal insulin
Used clinically in selected patients; combining incretin and basal insulin can improve control. Hypoglycemia risk rises — insulin adjustment is provider-only. Grade A.
Element
Concern
Gate
Basal insulin
Hypoglycemia
Provider dose adjust
+ Sulfonylurea
Higher hypo risk
GLP-1 RASulfonylurea
Possible but carries higher hypoglycemia concern because sulfonylureas drive insulin independent of glucose. Dose adjustment is provider-only. Grade A.
Element
Concern
Gate
Sulfonylurea
↑ hypoglycemia
Reduce dose
+ Another GLP-1 / GIP Agent
Blocked
SemaglutideTirzepatide
Duplicate incretin therapy is to be avoided — combining a GLP-1 RA with another GLP-1 or GLP-1/GIP agent increases adverse effects without clear benefit. Block recommendation. Grade D.
Combination
Status
Reason
GLP-1 + GLP-1/GIP
Block
Duplicate incretin
Liraglutide + Dulaglutide Together
Blocked
LiraglutideDulaglutide
Using both is duplicate GLP-1 therapy — explicitly blocked. Do not combine liraglutide and dulaglutide unless explicitly directed by a clinician (which is not a standard regimen). Grade D.
Combination
Status
Reason
Lira + dula
Block
Duplicate GLP-1
Oral Drugs & Procedures
Timing-sensitive
Oral medsAnesthesia
Delayed gastric emptying can affect absorption of some oral drugs and is relevant periprocedurally/around anesthesia — flag upcoming surgery and time absorption-sensitive orals appropriately. Grade A/B.
Context
Concern
Action
Oral absorption
Delayed
Time / monitor
Anesthesia
Aspiration risk
Periop review
No Research-Chemical Positioning
Blocked
CompoundedAutonomous dosing
These are FDA-approved biologics, not catalog peptides. Research-chemical/compounded substitution language, autonomous dosing, and "same as semaglutide/tirzepatide" marketing are blocked by Intrasigna. Grade D.
Claim
Status
Reason
Research-chemical sale
Block
Approved drug
"Same as semaglutide"
Block
Unsupported
05 · Safety & contraindications
Class safety, shared and specific.
Liraglutide and dulaglutide share the GLP-1 class safety profile: a thyroid C-cell boxed warning, gastrointestinal tolerability issues, and a handful of important warnings (pancreatitis, gallbladder disease, hypoglycemia with insulin/secretagogues, dehydration-related kidney injury). Monotherapy hypoglycemia risk is low because their action is glucose-dependent.
⛔ Boxed warning — Both drugs carry a boxed warning for thyroid C-cell tumors seen in rodents and are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2. The relevance of the rodent tumors to humans is not known.
Adverse reactions & key warnings (class)
Thyroid C-cell tumorsBoxed warning; MTC/MEN 2 contraindication. Human relevance undetermined.
NauseaThe most common effect; dose- and titration-related, usually transient.
Vomiting / diarrhea / constipationClass GI effects; mitigated by slow titration.
Decreased appetiteMechanism-related; contributes to weight effect.
PancreatitisDiscontinue if suspected; caution with prior history.
Gallbladder diseaseCholelithiasis/cholecystitis reported with GLP-1 RAs, especially with rapid weight loss.
Hypoglycemia (with insulin/SU)Low alone; rises with insulin or sulfonylureas — reduce those agents.
Acute kidney injuryVolume depletion from GI losses can worsen renal function — maintain hydration.
Increased heart rateModest resting-pulse increase reported with the class.
Diabetic retinopathy contextMonitor in patients with a history; rapid glycemic change is the relevant factor.
Gastroparesis / severe GICaution; delayed emptying may worsen symptoms.
Class adverse-effect frequency context
Safety · class reference
GLP-1 RA adverse effects — relative frequency
Effect
Relative frequency
Note
Nausea
Common
Titration-related, usually transient
Vomiting / diarrhea
Common
Class GI effects
Constipation / dyspepsia
Common
GI tolerability
Decreased appetite
Common
Mechanism-related
Gallbladder disease
Uncommon
Esp. with rapid weight loss
Pancreatitis
Rare
Discontinue if suspected
Severe hypersensitivity
Rare
Discontinue
Baseline & monitoring biomarkers
Biomarkers · baseline + monitoring
What to check and track
Marker
Why baseline
Monitoring
HbA1c
Diabetes severity / response
Glycemic response
Fasting glucose
Baseline control
Response / hypo pattern
Weight / BMI
Obesity-label context
Response & stopping criteria
eGFR
Therapy planning
CKD / dehydration risk
Urine ACR
CV/kidney risk
Diabetic kidney disease
Lipids
Cardiometabolic baseline
Risk modification
ALT/AST
MASLD context
Metabolic safety
Lipase/amylase (if symptoms)
Pancreatitis evaluation
If severe abdominal pain
Thyroid history / calcitonin (if indicated)
MTC/MEN 2 screening
Only if clinically justified
Pregnancy status (when applicable)
Reproductive safety
Avoid inappropriate exposure
Monitoring scaffold
Before starting
Screen for MTC/MEN 2 (contraindication), pancreatitis history, gastroparesis/severe GI disease, pregnancy, and concomitant insulin/sulfonylurea. Establish HbA1c, weight/BMI, renal function, and lipids. Flag upcoming procedures/anesthesia.
During titration
Track GI tolerability (nausea/vomiting), hydration and renal function if GI losses occur, and glucose if combined with insulin/sulfonylurea. Advance dose only as tolerated; watch for signs of pancreatitis or gallbladder disease.
Ongoing
Monitor A1c and weight for response (apply Saxenda stopping rule for the obesity indication), renal/UACR for cardiorenal risk, and reassess if severe persistent GI symptoms, suspected pancreatitis, or recurrent hypoglycemia occur.
Contraindications & safety gates
Condition
Concern
Severity · grade
Personal/family history of MTC
Boxed-warning contraindication
Contraindicated
MEN 2 syndrome
Boxed-warning contraindication
Contraindicated
Serious prior hypersensitivity
Allergy risk
Contraindicated
Type 1 diabetes / DKA
Not indicated (not insulin)
Avoid
History of pancreatitis
Caution / specialist review
Caution
Gastroparesis / severe GI disease
Worsened emptying
Caution
Insulin / sulfonylurea use
Hypoglycemia risk
Reduce / monitor
Pregnancy / planning
Reproductive safety
Provider review
CKD with dehydration risk
AKI from volume loss
Monitor renal/fluid
Upcoming surgery / procedure
Delayed emptying / aspiration
Periop review
Gallbladder disease
Cholelithiasis risk
Monitor
Severe persistent GI symptoms
Tolerability / dehydration
Reassess
Diabetic retinopathy history
Rapid glycemic change
Monitor
Hepatic impairment (dula)
Limited data
Caution
Duplicate GLP-1 / GIP therapy
Added risk, no benefit
Block
Pediatric (< 10 y / unapproved age)
Outside label age
Not established
Autonomous / non-Rx use
Approved biologic
Avoid
Research-chemical / compounded substitution
Unapproved positioning
Block
"Same as semaglutide/tirzepatide" claim
Unsupported equivalence
Block
Severe gastroparesis
Markedly delayed emptying
Caution / review
GRADE summary — Both liraglutide and dulaglutide are Grade A for their labeled type-2-diabetes and cardiovascular-outcome uses (LEADER, REWIND), with liraglutide additionally Grade A for chronic weight management (Saxenda). Risk level is high-gate because of the thyroid C-cell boxed warning and the pancreatitis/gallbladder/hypoglycemia/renal warnings, though glucose-dependent action keeps monotherapy hypoglycemia low. The decisive levers are MTC/MEN 2 screening, GI-gated titration, insulin/sulfonylurea dose reduction, and provider-managed use — never autonomous dosing, duplicate incretin therapy, or research-chemical positioning.
06 · Trials & evidence base
Two cardiovascular anchors, one drug class.
Both agents are backed by large randomized cardiovascular outcome trials — LEADER for liraglutide and REWIND for dulaglutide — plus extensive glycemic programs (and SCALE for liraglutide's obesity indication). REWIND stands out for its long follow-up and broad, largely primary-prevention population; LEADER established liraglutide's benefit in higher-risk patients. A head-to-head (AWARD-6) directly compared the two.
LEADER · CV
HR 0.87
Liraglutide, n=9340, MACE 13.0% vs 14.9% placebo over 3.8 y. Marso 2016.
REWIND · CV
HR 0.88
Dulaglutide, n=9901, MACE 12.0% vs 13.4%, median 5.4 y, broad population. Gerstein 2019.
SCALE · obesity
lira 3.0 mg
Liraglutide 3.0 mg, 56 wk, n=3731, significantly greater weight loss vs placebo. Pi-Sunyer 2015.
AWARD-6 · H2H
A1c =
Dula 1.5 mg matched lira 1.8 mg on A1c, less weight loss. Dungan 2014.
ALiraglutide · CV RCT
LEADER — liraglutide cardiovascular outcomes
Double-blind RCT of liraglutide (1.8 mg or max tolerated) vs placebo in 9,340 patients with T2D at high cardiovascular risk, median 3.8-year follow-up. The primary MACE composite (CV death, nonfatal MI, nonfatal stroke) occurred in 13.0% vs 14.9% (HR 0.87, 95% CI 0.78–0.97), with lower CV and all-cause death — establishing liraglutide's Grade A CV-outcome claim.
Double-blind RCT of once-weekly dulaglutide vs placebo in 9,901 patients with T2D, median 5.4-year follow-up — notable for a broad population including many without established CVD. Primary MACE was 12.0% vs 13.4% (HR 0.88, 95% CI 0.79–0.99), supporting dulaglutide's primary- and secondary-prevention CV benefit.
56-week double-blind RCT (n=3,731) of liraglutide 3.0 mg vs placebo in adults with obesity or overweight plus a comorbidity, all with lifestyle counseling. Liraglutide produced significantly greater weight loss and higher proportions achieving ≥5% and >10% loss — the evidence base for the Saxenda indication.
Open-label head-to-head trial: once-weekly dulaglutide 1.5 mg was non-inferior to once-daily liraglutide 1.8 mg for HbA1c reduction, but produced somewhat less weight loss — the direct comparison underpinning their relative positioning.
Victoza / Saxenda / Trulicity prescribing information
The FDA labels define each product's identity, indications, titration, the shared thyroid C-cell boxed warning, contraindications (MTC/MEN 2), warnings (pancreatitis, hypoglycemia with insulin/SU, AKI, gallbladder), and administration — the regulatory backbone of this page.
Both agents activate the Gs-coupled GLP-1 receptor, raising beta-cell cAMP to potentiate glucose-stimulated insulin secretion while suppressing glucagon in a glucose-dependent manner. This glucose-dependence is the class's defining safety feature, keeping monotherapy hypoglycemia risk low.
Native GLP-1 has a ~1.5–2-minute half-life due to DPP-4 and renal clearance. A 2025 GLP-1 RA pharmacokinetic review covers these structural strategies. Liraglutide uses fatty-acid acylation and albumin binding for a ~13-h half-life; dulaglutide uses an IgG4-Fc fusion for a ~5-day half-life — two distinct PK solutions reviewed across the GLP-1 RA class.
Current ADA standards prioritize GLP-1 receptor agonists with demonstrated cardiovascular benefit for people with T2D and atherosclerotic CV disease, CKD, or high CV risk, with updated guidance for GLP-1-based therapy in advanced CKD and cardiometabolic contexts.
Both trials reported renal composite benefits — driven largely by reductions in albuminuria (UACR) — supporting a cardiorenal role for GLP-1 RAs, with liraglutide's LEADER renal analysis and REWIND's prespecified renal outcomes both favorable.
Both agents slow gastric emptying and increase satiety, lowering postprandial glucose and caloric intake. The appetite effect is strong enough to underpin liraglutide's obesity label; the gastric effect is also why periprocedural and oral-absorption timing matter.
Both suppress glucagon in a glucose-dependent way, reducing hepatic glucose output while preserving the counter-regulatory glucagon response to true hypoglycemia — the mechanistic reason monotherapy hypoglycemia risk stays low and why risk rises only with insulin or secretagogues.
Victoza — T2D glycemic control (≥10 y) and MACE reduction with established CVD; Saxenda — chronic weight management in qualifying adults and adolescents ≥12; Trulicity — T2D glycemic control (≥10 y) and MACE reduction with established CVD or multiple CV risk factors.
Victoza starts at 0.6 mg daily (GI-tolerance step), then 1.2, then 1.8 mg; Saxenda escalates weekly 0.6 → 3.0 mg daily; Trulicity starts at an effective 0.75 mg weekly and steps to 1.5/3.0/4.5 mg — each titration is GI-gated.
Both carry the thyroid C-cell boxed warning and MTC/MEN 2 contraindication, alongside class warnings for pancreatitis, gallbladder disease, and acute kidney injury from volume depletion, with GI effects being the most common reactions. These define the high-gate safety posture.
Liraglutide 3.0 mg has a dedicated obesity indication (SCALE); dulaglutide can be associated with modest weight loss in T2D care but produces less weight loss than equipotent liraglutide on A1c (AWARD-6) and is not an obesity product — and neither should be marketed as equivalent to semaglutide or tirzepatide for weight loss.
This is the core of the page: a structured side-by-side. They share a receptor, a class safety profile, and cardiovascular evidence, but differ on dosing frequency, molecular design, obesity labeling, and convenience. Neither should be presented as equivalent to semaglutide or tirzepatide for weight loss — that is a blocked claim.
L1 · Consumer — Liraglutide and dulaglutide are prescription GLP-1 medications for type 2 diabetes. Liraglutide is taken daily and comes as Victoza (diabetes) and Saxenda (weight management); dulaglutide is taken once a week as Trulicity (diabetes and heart-risk reduction). Both can lower blood sugar, support weight loss, and reduce heart-related events — but they need a doctor's supervision, contraindication checks (especially certain thyroid cancers), and side-effect monitoring. They should never be used together or combined with another GLP-1 medication.
L2 · Clinical — Both are GLP-1 receptor agonists for T2D with cardiovascular-outcome evidence (LEADER for liraglutide, REWIND for dulaglutide). Liraglutide is daily, titrated 0.6→1.8 mg (Victoza) or 0.6→3.0 mg (Saxenda for weight management); dulaglutide is weekly, 0.75→4.5 mg (Trulicity). Both share the thyroid C-cell boxed warning and MTC/MEN 2 contraindication, GI tolerability issues, pancreatitis/gallbladder warnings, and hypoglycemia risk when combined with insulin or sulfonylureas. AWARD-6 showed weekly dulaglutide 1.5 mg matched daily liraglutide 1.8 mg on A1c with less weight loss.
L3 · Research — The pair exemplifies two engineering routes around native GLP-1's ~2-minute half-life. Liraglutide (C₁₇₂H₂₆₅N₄₃O₅₁, 3751 Da; 97% GLP-1 homology, Arg³⁴, C16 palmitoyl/γ-Glu at Lys²⁶) uses acylation and reversible albumin binding for daily dosing; dulaglutide (~63 kDa; 90% homology, Gly⁸/Glu²²/Gly³⁶) fuses two GLP-1 analogs to a modified IgG4 Fc for weekly dosing. Both signal via GLP-1R–Gs–cAMP for glucose-dependent insulinotropism and glucagonostasis, slow gastric emptying, and reduce intake. CV benefit (MACE HR 0.87/0.88) is partly mediated by HbA1c, weight, blood-pressure, and albuminuria effects, with renal composite benefit driven largely by reduced albuminuria.
08 · References & evidence
Source register.
Evidence grades reflect the strength of support for the specific claim cited, not the prestige of the journal. The FDA labels and the LEADER, REWIND, SCALE, and AWARD-6 randomized trials are the firmest evidence; guideline, pharmacokinetic, and database sources anchor mechanism, identity, and positioning.